Applying scientific rigor and creativity to translate RNA discoveries into innovative products

Innovative Therapeutics

SomaGenics' therapeutic programs use proprietary RNA interference methods to target hepatitis C, psoriasis, and HIV.  Our lead program utilizes discoveries we have made in direct delivered small hairpin RNA (shRNA), which differ from the more commonly used siRNA in consisting of only a single RNA strand that folds back on itself, instead of two separate strands.  SomaGenics' proprietary shRNA design has advantages of potency, simplicity, and novelty.

scientist in lab

RNA Detection Technologies

SomaGenics has developed novel diagnostic platforms for the detection of both long and short nucleic acids. Our invention of the RNA Lasso™ has led to the development of a novel class of diagnostic probes having a superior combination of sensitivity and selectivity. We are currently in the development stage of miR-ID™, a novel microRNA detection system.

Reputation for Excellence

SMGX believes that close ties with the scientific community through publishing and exposing its innovation to scrutiny leads to higher quality science and products. Accordingly, the company regularly publishes its research advances in respected peer-reviewed journals. The validation by peer reviewers of its approach and the quality of its science is also reflected in its outstanding record of attracting competitive grant funding. Amongst other grants, the company has received over 3 million dollars from the National Institutes of Health for the preclinical development of its HCV program.